SOURCE: Ablynx

April 13, 2010 15:28 ET

SPO OVER-ALLOTMENT OPTION PARTIALLY EXERCISED

GHENT, BELGIUM--(Marketwire - April 13, 2010) -



GHENT, Belgium - 13 April 2010 - Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies(ÂÂ(r)), announces that KBC Securities, acting on behalf of the bank underwriting syndicate of its Secondary Public Offering (the "SPO" or "Offering") completed in March 2010, has partially exercised the Over- allotment Option on 13 April 2010, in accordance with provisions contained in the SPO prospectus.

At the SPO, 400,000 over-allotment shares had been allotted. Such shares were lent by the Lending Shareholders (ACP IV, L.P., KBC Private Equity NV and VIB VZW). The partial exercise of the Over-allotment Option will result in a total of 219,107 shares being sold by the Lending Shareholders at the SPO offer price, i.e. EUR7.5 per share. On 31 March, 6 and 8 April 2010, stabilisation transactions were carried out for a total of 180,893 shares all at the offer price i.e. EUR7.5 per share.

As a result, a total of 6,885,774 shares of Ablynx NV will have been placed on the market in the Offering, equal to approximately EUR51.64 million (at the offer price).

Transfer and payment of shares related to the partial exercise of the Over-allotment Option will take place on 16 April 2010.

KBC Securities NV and UBS Investment Bank acted as Joint Global Coordinators and Joint Bookrunners, while Piper Jaffray Ltd. acted as Co-Manager to the Offering.

-ends-

About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised EUR50 million through an SPO in March 2010.






[HUG#1403325]





Complete version of the press release : http://hugin.info/137912/R/1403325/357618.pdf

Contact Information

  • For more information, please contact Ablynx:

    Dr. Edwin MosesChairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e:edwin.moses@ablynx.com

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e:eva-lotta.allan@ablynx.com

    Wim Ottevaere
    Chief Financial Officer
    t: +32 (0)9 262 00 08
    e:wim.ottevaere@ablynx.com